FHCRC Collaborates with Korean Company on Proteomic Microarrays

Fred Hutchinson Cancer Research Center (FHCRC; Seattle, WA, USA) and NSB Postech, Inc. (NSB; Hyo-ja, Korea) have entered into an agreement to coordinate their efforts and to determine the efficacy of the NSB's NanoCones surface technology in creating high quality proteomic microarrays to be used in the study of human diseases.

NSB is a biotech company that possesses a proprietary microarray technology and expertise in nanoscale controlled surface chemistry. The collaboration between the companies will involve a comparison of slides created with NSB's newly developed NanoCones surface technology and the current industry standard. NSB will fund the collaboration.

Antibody or protein microarrays are glass microscope slides onto which very small amounts of thousands of different antibodies or proteins have been affixed at distinct locations. Antibody microarrays can be used to simultaneously determine the level of each antibody's specific binding partner in complex mixtures such as blood; thousands of different assays can be performed with small amounts of sample.

"We are excited about the preliminary data that has been generated when antibodies were arrayed using the NanoCones technology. We hope this will make our antibody arrays more sensitive and accurate,” said Dr. Paul Lampe, member of the Hutchinson Center's Public Health Sciences Division and associate program head of molecular diagnostics.


Related Links:
Fred Hutchinson Cancer Research Center
NSB Postech